Xolair
My Prescription
Payment
Select pharmacy
$3,206.35
$30.00 due at pharmacy
$3,206.35 - $30.00 = $3,176.35
$3,176.35 remaining balance
You will be given your coupon after you complete your purchase with PayPal.
WalgreensPowered by$3,206.35
Print or send this coupon to your phone
WalgreensPowered byAbout Xolair
Drug Details
Omalizumab, marketed under the name Xolair, is a medication designed to manage and prevent symptoms related to allergic conditions. It is particularly useful for individuals who suffer from moderate-to-severe allergic asthma, uncontrolled nasal polyps, and chronic spontaneous urticaria (a type of hives with no known cause). Additionally, Xolair is beneficial in reducing the risk of severe allergic reactions following accidental exposure to specific food allergens. Primarily, Xolair functions as a monoclonal antibody targeting the immunoglobulin E (IgE) protein within the immune system. By doing so, it helps in modulating the immune response, thus alleviating allergic symptoms. This medication is administered via an injection under the skin, typically every 2 to 4 weeks, and is suitable for both adults and children. While Xolair is effective in controlling symptoms, it is essential to use it consistently as prescribed, as it does not provide immediate relief and should not be relied upon for emergency treatment during sudden asthma attacks or severe allergic reactions. In such events, a quick-relief inhaler like albuterol should be used as directed by a healthcare provider. Common side effects may include headache, stomach pain, and dizziness. It is important to consult with a healthcare professional before beginning Xolair to ensure its safety and efficacy based on individual health needs.
Price history for Xolair
1 Syringe, 2ML of 300MG/2ML
Average retail price for Xolair
Average SaveHealth price for Xolair
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Xolair dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 0.5ML of 75MG/0.5ML | 1 Pen | $806.16 | $806.16 |
| 0.5ML of 75MG/0.5ML | 2 Pens | $1,607.57 | $803.79 |
| 0.5ML of 75MG/0.5ML | 3 Pens | $2,408.97 | $802.99 |
| 1ML of 150MG/ML | 1 Pen | $1,605.54 | $1,605.54 |
| 1ML of 150MG/ML | 2 Pens | $3,206.34 | $1,603.17 |
| 1ML of 150MG/ML | 3 Pens | $4,807.13 | $1,602.38 |
| 2ML of 300MG/2ML | 1 Pen | $3,206.35 | $3,206.35 |
Xolair FAQs
XOLAIR (omalizumab) is a medication used to treat moderate to severe persistent asthma in patients who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. It is also used for chronic idiopathic urticaria in patients who remain symptomatic despite antihistamine treatment. XOLAIR works by binding to immunoglobulin E (IgE), which plays a key role in allergic reactions, thereby reducing the amount of IgE available to trigger allergic responses.
XOLAIR (omalizumab) is not specifically approved for the prevention of anaphylaxis. It is primarily used to treat moderate to severe persistent asthma and chronic idiopathic urticaria. While it may have some effect on reducing allergic reactions, it should not be relied upon as a preventive measure for anaphylaxis. Patients at risk for anaphylaxis should continue to carry and use an epinephrine auto-injector as prescribed by their healthcare provider.
Candidates for XOLAIR (omalizumab) typically include individuals with moderate to severe persistent asthma who are 6 years of age or older and have a positive skin test or in vitro reactivity to a perennial aeroallergen. It is also used for patients with chronic idiopathic urticaria who are 12 years of age or older and remain symptomatic despite antihistamine treatment. A healthcare provider will evaluate the patient's specific condition, medical history, and other factors to determine if XOLAIR is appropriate.
XOLAIR (omalizumab) does not cure urticaria, but it can help manage and reduce the symptoms of chronic spontaneous urticaria in patients who do not respond adequately to antihistamines. It works by targeting and reducing the activity of IgE, an antibody involved in allergic reactions. Treatment with XOLAIR can lead to a significant reduction in hives and itching, improving the quality of life for patients. However, it is important for patients to continue regular consultations with their healthcare provider to monitor their condition and adjust treatment as necessary.
Xolair (omalizumab) has been shown to be effective in treating chronic spontaneous urticaria (hives) in patients who do not respond to antihistamines. Clinical studies have demonstrated that a significant number of patients experience a reduction in hives and itchiness. While individual responses can vary, many patients report a noticeable improvement in symptoms. It is important for patients to discuss their specific condition and treatment expectations with their healthcare provider.